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Background: Guidelines recommend extended thromboprophylaxis following colectomy for 
malignant disease, but not for non-malignant disease. The aim of this study was to determine 
absolute and relative rates of venous thromboembolism (VTE) following colectomy by 
indication, admission type and time after surgery. 
Methods: A cohort study of patients undergoing colectomy in England was undertaken using 
linked primary (Clinical Practice Research Datalink) and secondary (Hospital Episode 
Statistics) care data (2001–2011). Crude rates and adjusted hazard ratios (HRs) were 
calculated for the risk of first VTE following colectomy using Cox regression analysis. 
Results: Some 12 388 patients were identified; 312 (2.5 per cent) developed VTE after 
surgery, giving a rate of 29.59 (95 per cent c.i. 26.48 to 33.06) per 1000 person-years in the 
first year after surgery. Overall rates were 2.2-fold higher (adjusted HR 2.23, 95 per cent c.i. 
1.76 to 2.50) for emergency compared with elective admissions (39.44 versus 25.78 per 1000 
person-years respectively). Rates of VTE were 2.8-fold higher in patients with malignant 
disease versus those with non-malignant disease (adjusted HR 2.84, 2.04 to 3.94). The rate of 
VTE was highest in the first month after emergency surgery, and declined from 121.68 per 
1000 person-years in the first month to 25.65 per 1000 person-years during the rest of the 
follow-up interval. Crude rates of VTE were similar for malignant and non-malignant disease 
(114.76 versus 120.98 per 1000 person-years respectively) during the first month after 
emergency surgery. 
Conclusion: Patients undergoing emergency colectomy for non-malignant disease have a 
similar risk of VTE as patients with malignant disease in the first month after surgery. 
 
+A: Introduction 
More than 33 000 colectomies are performed in England each year, and nearly 250 000 in the 
USA, for non-malignant and malignant disease, with nearly one-quarter occurring as an 
emergency procedure1. Recent international guidance has recommended that patients 
undergoing colectomy for malignant disease should receive extended pharmacological 
thromboprophylaxis for 4 weeks after surgery, based on evidence from four randomized trials 
including 901 patients, of whom over 80 per cent had malignant disease2–5. A subsequent 
systematic review6 of these studies reported a reduction in overall venous thromboembolism 
(VTE) from 14.3 to 6.1 per cent (odds ratio 0.41, 95 per cent c.i. 0.26 to 0.63). However, no 
such evidence exists for patients undergoing colectomy for non-malignant disease, who 
account for 40–50 per cent of patients having a colectomy7,8. Hence, no specific guidance has 
been issued on extended VTE prophylaxis in this group, despite these patients having 
underlying medical conditions such as ulcerative colitis, Crohn’s disease and diverticular 
disease that are associated with an inherent increased risk of VTE compared with that in the 
general population, in both the ambulatory and hospital setting9–11. Previous studies 
describing the risk of VTE following colectomy for non-malignant disease have had limited 
follow-up (30 days), reducing their ability to quantify the highest risk period for VTE 
following surgery7,12. Similarly, studies reporting the risk of VTE following colectomy for 
malignant disease have used a limited 30-day follow-up13, or have compared the risk of VTE 
after colectomy with that in patients with advanced metastatic disease, and hence have 
concluded, probably erroneously, that the risk of VTE is reduced after surgery14. 
Published studies on VTE following colectomy have failed to quantify the risk in terms 
of indication for surgery (particularly non-malignant indications), timing of surgery 
(emergency versus elective), and duration or timing of the highest risk of VTE after 
operation. The aim of the present study was to determine the magnitude and duration of risk 
of VTE following colectomy by indication for surgery and timing of surgery using linked 
electronic healthcare data from England15. 
+A: Methods 
The study was approved by the Independent Scientific Advisory Committee approval board 
(Protocol 11-051R). 
+B: Data sources 
The Clinical Practice Research Database (CPRD) is a primary care database containing 
diagnostic and prescription data for approximately 13 million people of the general 
population in the UK, with 3·4 million active patients contributing data. Diseases are coded 
within the CPRD using Read codes which have been used by clinicians to record data within 
primary care since 1985.16  
Hospital Episode Statistics (HES) collects a record for each episode of admitted patient 
care delivered in England, either by National Health Service (NHS) hospitals or delivered in 
the independent sector but commissioned by the NHS. It has collected data since 1989, with 
more than 15 million new records added each year. Records are coded using a combination of 
ICD-10 codes for diagnosis at discharge along with Office of Population, Censuses and 
Surveys Classification of Surgical Operations and Procedures (OPCS 4) detailing procedures 
performed. Increasingly HES data are being used to study surgical diseases, with a recent 
systematic review17 reporting that approximately two-thirds of studies published using these 
data concern surgical conditions. 
Death certificate data from the Office for National Statistics were also used. 
Anonymized patient identifiers from CPRD and HES were linked by a trusted third party by 
using the NHS number, date of birth, postcode and sex. Most patients were matched exactly 
according to NHS number (over 90 per cent of patients are linked in this way), with the 
remaining patients linked probabilistically on the basis of postcode, date of birth and sex. In 
the version employed, 53.0 per cent of practices in the CPRD are linked to HES, representing 
a 3.0 per cent sample of the population of England. These data have been shown previously18 
to be similar in terms of age, sex and geographical distribution to data from the UK 
population. 
+B: Cohort 
The cohort was identified using OPCS codes for any colectomy from HES data between 2001 
and 2011 (Appendix S1, supporting information). Operations confined to or including the 
rectum and anal canal were excluded. Person-time at risk commenced on the day after 
surgery for the overall analysis; therefore VTEs recorded on the same day as the operation 
were not included in the analysis. Patients were followed up until they developed a VTE 
event, died, left a participating general practice, or for 1 year after surgery. Patients were 
excluded if they were: not in a linked general practice or had had a VTE before the admission 
date for colectomy, as these patients have an inherently increased risk of postoperative VTE. 
Previous VTE was defined using the same definition as for the entire study. 
+B: Exposures 
Patients were identified who had a colorectal cancer diagnosis in the CPRD and HES data 
(ICD-10 sections C18–20, excluding C18.1 Appendix). The non-malignant diagnoses were 
confirmed from the ICD-10 discharge codes associated with the admission, including 
inflammatory bowel disease (Appendix S1, supporting information), diverticular disease 
(Appendix S1) and other. Co-morbidity was determined from the CPRD and classified using 
the Charlson index before admission for surgery19. Admission type was defined as elective or 
emergency, based on the type of admission recorded for the surgical procedure. Smoking 
status was classified as never, ever, current or missing, based on CPRD smoking records 
before the operation. Body mass index (BMI) was recorded from CPRD records, and patients 
were classified as having a BMI of less than 30 kg/m2, 30 kg/m2 or more, or missing data. 
Laparoscopic surgery was defined as any surgery accompanied by a laparoscopic code. 
Prescriptions for the oral contraceptive pill and hormone replacement therapy (HRT) were 
identified from the CPRD, and users were classified as current if the prescription was within 
3 months of the index operation. 
+B: Outcome definition 
VTE diagnosis was determined from medical codes in the CPRD and HES. These were 
considered to indicate a valid VTE event if supported by either: a prescription for an 
anticoagulant or other evidence of treatment in an anticoagulation clinic (such as a medical 
code) between 15 days before and 90 days after the VTE diagnosis, or a date of death within 
30 days of the event. Additionally, an underlying cause of death of VTE was included as 
evidence of a VTE diagnosis. The definition using primary care data alone has been validated 
previously20 and used in the authors’ previous studies of VTE21,22. 
+B: Statistical analysis 
The date of diagnosis of VTE was taken to be the episode start date for VTEs occurring 
within the same hospital admission as the index operation. Absolute rates of VTE (per 1000 
person-years) were calculated by dividing the number of individuals with VTE by the person-
time at risk for the first year of follow-up after operation. This was done overall and then 
separately for each exposure of interest. Patients with missing data were analysed as a 
separate category, and rates and risk were presented separately for them. A Cox proportional 
hazards model was then created to include all exposures, to estimate hazard ratios (HRs) and 
95 per cent c.i. The risk of VTE was then evaluated by indication for surgery and type of 
admission, adjusting for age and co-morbidity. A female-only analysis was performed in 
order to account for current use (within 3 months of surgery) of the oral contraceptive pill or 
HRT, given their known association with an increased risk of VTE23. Age was fitted as an 
interaction term in the models using likelihood ratio tests to look for the presence of a 
significant interaction. A further analysis was undertaken of the rates of VTE by calendar 
month after surgery in order to define the period of greatest risk up to 12 weeks. A sensitivity 
analysis was performed of all patients from the date of hospital discharge, excluding patients 
who had an in-hospital VTE, to determine the rates of VTE after discharge. All data 
management and analyses were performed using Stata® version 12 (StataCorp, College 
Station, Texas, USA). 
+A: Results 
In total, 12 388 patients had a colectomy and 312 (2.5 per cent) developed VTE in the first 
year after surgery. The proportion of men and women undergoing emergency surgery was 
similar; however, in the elective setting the proportion of women who had surgery for non-
malignant was greater than that for malignant disease (56.4 versus 45.2 per cent; P < 0.001, 
χ2 test) (Table 1). Patients undergoing surgery for non-malignant disease were younger than 
those undergoing surgery for malignant disease (median (i.q.r.) 62 (46–74) versus 72 (64–79) 
years respectively; P = 0.001, Kruskal–Wallis test). Patients undergoing emergency or 
elective surgery for malignant disease were more likely to be ever or current smokers than 
those with non-malignant disease (Table 1) (P < 0.001, χ2 test). In total, 12.5 per cent of the 
patients (1547 of 12 388) had a laparoscopic procedure during the study interval, increasing 
to 33.7 per cent (302 of 895) in the final year of the study. 
In the emergency setting, 1750 (44.4 per cent) of 3938 patients had surgery for 
malignant disease; of those undergoing surgery for non-malignant disease, 502 (22.9 per 
cent) of 2188 were for inflammatory bowel disease (IBD) and 651 (30.0 per cent) of 2188 
were for diverticular disease, with the remainder for other indications. In the elective setting 
6559 (77.6 per cent) of 8450 patients underwent surgery for malignant disease; of those 
having surgery for non-malignant disease 527 (27.9 per cent) were for IBD and 579 (30.6 per 
cent) for diverticular disease, with the remainder for other indications. 
+B: Venous thromboembolism rates overall, by admission type  and indication 
The overall rate of VTE following colectomy for any indication was 29.59 (95 per cent c.i. 
26.48 to 33.06) per 1000 person-years at 1 year. The rate of VTE was highest in the first 
month after emergency surgery, and declined from 121.68 per 1000 person-years in the first 
month to 25.65 per 1000 person-years during the rest of the follow-up interval. The overall 
rate was 2.2-fold higher (adjusted HR 2.23, 95 per cent c.i. 1.76 to 2.50) for emergency 
compared with elective admissions (crude rate 39.44 versus 25.78 per 1000 person-years 
respectively) in the year after surgery. For malignant disease, rates of VTE were 2.8-fold 
higher (adjusted HR 2.84, 2.04 to 3.94) than for non-malignant disease (36.85 versus 14.56 
per 1000 person-years respectively). When patients in the non-malignant group without a 
clear indication for surgery were excluded, there was little difference in the absolute rates 
(14.56 versus 10.94 per 1000 person-years, including and excluding patients without a clear 
indication respectively). 
Laparoscopic surgery was not associated with a reduction in risk of VTE in the first 
year after surgery (unadjusted HR 0.91, 95 per cent c.i. 0.65 to 1.28). For women, the overall 
rate of VTE was 2.3-fold higher (adjusted HR 2.23, 1.59 to 3.13) for emergency compared 
with elective admissions in the year after surgery. When further adjustment was made for 
current use of either HRT or the oral contraceptive pill this association did not change 
(adjusted HR 2.24, 1.60 to 3.14); thus, no adjustment for these variables was made in 
subsequent analyses. 
+B: Overall rates of venous thromboembolism 
+C: Elective colectomy 
Patients who had elective colectomy for non-malignant disease had the lowest crude rate of 
VTE (6.31 per 1000 person-years) (Table 2). The crude rate of VTE following elective 
colectomy increased with increasing age, peaking in those aged over 60 years (36.33 per 
1000 person-years). The risk of VTE increased with increasing age, although the effects of 
age were attenuated when accounting for indication, suggesting an interaction between age 
and indication (P < 0.005, likelihood ratio test). When stratified by indication, the risk of 
VTE by age increased for patients with a non-malignant indication, peaking in those over 80 
years old (crude rate 20.80 per 1000 person-years), but there was no increase in patients with 
a malignant indication. 
+C: Emergency colectomy 
Patients undergoing an emergency colectomy for malignant disease had a 2.4-fold increase in 
risk of VTE in the year following colectomy compared with those with a non-malignant 
indication (Table 3). The risk of VTE increased with increasing age, but the effects of age 
were attenuated when accounting for indication, suggesting an interaction between age and 
indication (P < 0.001, likelihood ratio test). When stratified by indication, the risk of VTE by 
age increased for patients with a non-malignant indication, peaking in those over the age of 
60 years (crude rate 37.62 per 1000 person-years), but there was no increase in patients with a 
malignant indication. 
+B: Rates in first month after surgery 
+C: Elective surgery 
Patients who had an elective colectomy for malignant disease had a 3.8-fold increased risk of 
VTE in the first month after surgery versus patients with non-malignant disease (HR 3.81, 95 
per cent c.i. 0.90 to 15.99), although this was not significant (Table 4). The absolute rate of 
VTE in all patients fell after the first postoperative month (Fig. 1). 
+C: Emergency surgery 
Patients undergoing emergency colectomy had a similar cumulative incidence of VTE in the 
first month after surgery regardless of indication, with a higher absolute rate in those with a 
malignant indication: 120.98 per 1000 person-years versus 114.76 per 1000 person-years in 
those with non-malignant disease (HR 1.12, 95 per cent c.i. 0.56 to 2.27) (Table 4 and 
Fig. 2). 
The rate of VTE following a non-malignant emergency colectomy was 2.0-fold greater 
than that for an elective colectomy with a malignant indication in the first month after surgery 
(absolute rate 114.76 versus 61.83 per 1000 person-years respectively; HR 2.04, 95 per cent 
c.i. 1.13 to 3.74). Following the first month after surgery, the absolute rate of VTE in all 
patients fell during the remainder of the year but remained highest in those undergoing 
emergency surgery for malignant disease (54.42 per 1000 person-years) (Table 4). 
+B: Sensitivity analysis after discharge from hospital 
+C: Elective surgery 
In the first month after hospital discharge the absolute rates of VTE were similar to those in 
the first month after surgery (non-malignant: 13.18 versus 12.98 per 1000 person-years; 
malignant: 68.76 versus 61.83 per 1000 person-years) (Tables 4 and 5). 
+C: Emergency surgery 
In the first month after discharge from hospital the absolute rate of VTE was lower following 
emergency admission for non-malignant disease compared with that in the first month after 
surgery (78.01 versus 114.76 per 1000 person-years). A reduction was also seen in the month 
following discharge in patients with a malignant indication: 106.38 per 1000 person-years 
versus 120.98 per 1000 person-years in the first month after surgery (Tables 4 and 5). 
+A: Discussion 
This study found an overall 1-year incidence of VTE following colectomy of 2.5 per cent. 
The highest overall absolute rates of VTE occurred after emergency surgery for malignant 
disease, and rates increased with age for non-malignant indications, although not in patients 
with cancer. Undoubtedly, the period of greatest risk for VTE following colectomy is the first 
month after surgery: around 0.5 per cent by the end of this period following any colectomy, 
and 1.0 per cent with an emergency admission. Of particular note is the fact that patients 
undergoing emergency colectomy for either a malignant or a non-malignant indication had 
similar high rates of VTE in the early postoperative period. Given that current guidance 
recommends extending VTE prophylaxis following colectomy for malignancy to 28 days 
after surgery, randomized clinical trials of the benefits of extended prophylaxis may be 
warranted in those patients having an emergency colectomy for non-malignant disease. 
This study used linked data to identify patients undergoing colectomy from population-
based data, with identification of operative procedures from secondary care along with 
defining VTE in a validated manner from primary20 and secondary care, and is thus uniquely 
placed to quantify VTE risk accurately. The identification of VTE following discharge from 
hospital relies on clinical suspicion of the general practitioner and subsequent referral for 
investigation, thereby minimizing the surveillance bias that may occur in patients identified 
solely in hospital, as has been suggested in other studies24. The indication for surgery in 
patients with non-malignant disease was not classified specifically in 25.2 per cent of patients 
(1029 of 4079) and this figure is in keeping with data previously published using stand-alone 
HES data25. Furthermore, when these patients were excluded from the analysis, the absolute 
rates of VTE remained broadly similar, suggesting that the risk of VTE in these patients was 
no greater than that of patients with a clear indication for surgery. Although the authors were 
unable to identify patients who received thromboprophylaxis at or around the time of surgery 
during the study interval (2001–2011), only in the last year of the study were there 
recommendations for prolonged thromboprophylaxis following surgery in the UK. Uptake of 
this by colorectal surgeons at this time was poor26, so patients would at most have received 
low molecular weight heparin while an inpatient following surgery15. 
The sensitivity analysis of patients following discharge demonstrates that patients were 
still at increased risk of VTE after discharge, regardless of whether they had received 
thromboprophylaxis in hospital. In addition, rates of thromboprophylaxis at this time were 
low, with the ENDORSE study27 estimating that only 50 per cent of patients received 
appropriate thromboprophylaxis, with a lower proportion in those undergoing emergency 
surgery – in whom the present study found the highest absolute rates of VTE. Nevertheless 
the possibility cannot be excluded that rates of VTE might have been higher in some groups 
than was observed in this study, precisely because they received longer prophylaxis. 
The potential effects of laparoscopic resection on the rates of VTE could not be 
assessed fully. Laparoscopic resection rates reported here were low, as it was during the study 
period that laparoscopic resection rates began to increase. The finding of approximately one-
third of resections being performed laparoscopically by the end of the study is in keeping 
with data from the National Bowel Cancer Audit28. Further studies are required to assess the 
potential benefits of laparoscopic surgery in this group of patients. 
Rates of VTE following a diagnosis of colorectal cancer were recently the subject of a 
systematic review and meta-analysis29, which reported an overall incidence of 16 per 1000 
person-years based on four studies reporting incidence in average-risk populations. Few 
studies have, however, described the risk of VTE following surgery for malignant disease, 
with conflicting results being reported based on the comparison population used. Two 
population-based studies14,30 reporting on VTE risk following a diagnosis of colorectal cancer 
found a decreased risk of VTE after surgery; however, the comparison group comprised 
patients who did not have surgery because of advanced disease or significant co-morbidity, 
who have the greatest risk of VTE. Alcalay and colleagues14 reported a 6-month rate of VTE 
after surgery of 40 per 1000 patient-years, which is similar to the present 6-month rate of 
48.08 (95 per cent c.i. 41.57 to 55.62) per 1000 person-years. Their study, however, did not 
report rates by emergency or elective resection. A study13 using data from the American 
College of Surgeons National Surgery Quality Improvement Program National Surgery 
Quality Improvement Program (NSQIP) database reported an overall 30-day VTE rate of 2.0 
per cent (446 of 21943) following colectomy for colorectal cancer, but gave limited 
information on timing after surgery as follow-up was limited to 30 days, and did not report 
rates by emergency and elective resections. A further study31 using NSQIP data from 2005 to 
2008 reported an overall VTE rate of 2.5 per cent following colectomy, with a postdischarge 
rate of 0.7 per cent, which is in keeping with the 0.5 per cent rate found in the present study 
for all patients following colectomy. Fleming and co-workers31 found no difference in VTE 
rates between non-malignant and malignant disease (both 0.7 per cent), although they did not 
report rates according to whether surgery was performed as an emergency or electively. The 
present study, however, has shown a clear increased risk for malignant disease, of 2.4-fold in 
the first year after emergency surgery and 4.2-fold following elective surgery. 
Few studies have reported the risk of VTE after surgery for non-malignant disease. A 
study12 using data from the NSQIP database reported a 30-day risk of VTE following surgery 
for IBD of 2.3 per cent (242 of 10 431). This is higher than the 30-day rate for non-malignant 
disease in the present study; however, it is not clear whether Wallaert et al.12 excluded 
patients who had had a VTE previously, as in the present study. Their study did, however, 
find that emergency surgery resulted in a 1.8-fold (odds ratio 1.8, 95 per cent c.i. 1.2 to 2.6) 
increase in risk of VTE compared with elective surgery. Sweetland and colleagues32 reported 
an increased VTE risk in women undergoing gastrointestinal surgery (relative risk 56.0, 95 
per cent c.i. 39.4 to 80.4) and cancer surgery (relative risk 91.6, 73.9 to 113.4) compared with 
the risk in women who did not have surgery, with the greatest risk in the first 6 weeks after 
operation. These authors were, however, unable to describe the risk in detail according to the 
timing of surgery (emergency or elective), or indication for surgery in terms of non-malignant 
and malignant disease. 
Current guidance from the National Institute for Health and Care Excellence15 and the 
American College of Chest Physicians33 suggests that patients undergoing colectomy for 
malignant disease should receive 28 days (4 weeks) of extended pharmacological prophylaxis 
after surgery. This guidance is supported by the present findings, which indicate an increased 
risk of VTE in patients undergoing surgery for malignant disease in both the elective and 
emergency setting that extends beyond the inpatient period. However, the present results also 
indicate that patients having emergency surgery for non-malignant disease have a similar 
increased risk of VTE during the 30 days after surgery to that of patients with malignant 
disease operated on as an emergency. Indeed, the magnitude of the risk in patients 
undergoing emergency non-malignant colectomy was greater than that of patients undergoing 
colectomy for malignant disease in the elective setting, who currently receive extended 
prophylaxis. Given the findings of the ENDORSE study27, every effort should be made to 
assess risk in these patients before operation and ensure that appropriate thromboprophylaxis 
is prescribed during their hospital stay. Interventional studies assessing the benefit and risks 
of extended prophylaxis in patients undergoing emergency colectomy for non-malignant 
disease may be warranted. 
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<TYPESETTER: PLEASE FOLLOW MARK-UPS OF FIGS 1 & 2> 
Fig. 1 Cumulative incidence of venous thromboembolism (VTE) following elective 
admission by indication for surgery 
 
Fig. 2 Cumulative incidence of venous thromboembolism (VTE) following emergency 
admission by indication for surgery 
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Table 1 Demographics of colectomy cohort, by admission type and indication for surgery 
 
Emergency (n = 3938) Elective (n = 8450) 
Non-malignant 
(n = 2188) 
Malignant 
(n = 1750) 
Non-
malignant 
(n = 1891) 
Malignant 
(n = 6559) 
Age (years) 
    
< 40 389 (17.8) 33 (1.9) 362 (19.1) 57 (0.9) 
40–49 218 (10.0) 72 (4.1) 218 (11.5) 212 (3.2) 
50–59 310 (14.2) 177 (10.1) 318 (16.8) 767 (11.7) 
60–69 409 (18.7) 356 (20.3) 459 (24.3) 1774 (27.0) 
70–79 502 (22.9) 579 (33.1) 373 (19.7) 2329 (35.5) 
80–89 360 (16.5) 533 (30.5) 161 (8.5) 1420 (21.6) 
Sex 
    
M 985 (45.0) 825 (47.1) 824 (43.6) 3598 (54.9) 
F 1203 (55.0) 925 (52.9) 1067 (56.4) 2961 (45.1) 
No. of co-morbidities 
    
0 1120 (51.2) 739 (42.2) 1058 (55.9) 2136 (32.6) 
1 466 (21.3) 327 (18.7) 401 (21.2) 880 (13.4) 
2 285 (13.0) 323 (18.5) 240 (12.7) 1848 (28.2) 
≥ 3 317 (14.5) 361 (20.6) 192 (10.2) 1695 (25.8) 
Body mass index (kg/m2) 
    
< 30 1356 (62.0) 1140 (65.1) 1253 (66.3) 4370 (66.6) 
≥ 0 377 (17.2) 300 (17.1) 354 (18.7) 1370 (20.9) 
Missing 455 (20.8) 310 (17.7) 284 (15.0) 819 (12.5) 
Smoking status 
    
Never 517 (23.6) 274 (15.7) 405 (21.4) 730 (11.1) 
Ever 887 (40.5) 861 (49.2) 853 (45.1) 3322 (50.6) 
Current 563 (25.7) 487 (27.8) 523 (27.7) 2209 (33.7) 
Missing 221 (10.1) 128 (7.3) 110 (5.8) 298 (4.5) 
 
  
Table 2 Rates of venous thromboembolism for elective admission, by indication, age, co-
morbidity using the Charlson index, body mass index and smoking 
  Rate per 1000 person-years Unadjusted HR Adjusted HR* 
Indication 
   
Non-malignant 6.31 (3.49, 11.37) 1.00 (reference) 1.00 (reference) 
Malignant 31.59 (27.35, 36.49) 4.03 (2.20, 7.41) 4.16 (2.24, 7.72) 
Age (years) 
   
< 40 – – – 
40–49 9.79 (3.67, 26.07) 1.00 (reference) 1.00 (reference) 
50–59 21.85 (14.39, 33.18) 2.22 (0.77, 6.45) 1.76 (0.61, 5.13) 
60–69 36.33 (28.93, 45.63) 3.69 (1.35, 10.08) 2.67 (0.97, 7.37) 
70–79 27.91 (21.96, 35.45) 2.02 (1.03, 7.75) 1.98 (0.72, 5.50) 
> 80 21.37 (14.85, 30.75) 1.44 (0.76, 6.12) 1.56 (0.54, 4.50) 
No. of co-morbidities 
   
0 25.08 (19.94, 31.55) 1.00 (reference) 1.00 (reference) 
1 27.76 (19.63, 39.25) 1.06 (0.70, 1.61) 1.04 (0.68, 1.59) 
2 26.48 (20.07, 34.93) 0.96 (0.67, 1.38) 0.81 (0.56, 1.16) 
3 24.83 (18.29, 33.73) 0.89 (0.61, 1.30) 0.72 (0.48, 1.07) 
Body mass index (kg/m2) 
   
< 30 21.45 (17.78, 25.88) 1.00 (reference) 1.00 (reference) 
≥ 30 41.49 (32.48, 53.01) 1.88 (1.38, 2.56) 1.84 (1.34, 2.51) 
Missing 23.49 (15.61, 35.34) 1.17 (0.74, 1.83) 1.20 (0.73, 1.95) 
Smoking status 
   
Never 18.84 (12.02, 29.54) 1.00 (reference) 1.00 (reference) 
Ever 26.72 (21.99, 32.47) 1.36 (0.83, 2.22) 1.19 (0.73, 1.96) 
Current 28.2 (22.27, 35.70) 1.39 (0.84, 2.31) 1.18 (0.71, 1.98) 
Missing 19.04 (9.08, 39.93) 1.08 (0.45, 2.56) 0.92 (0.37, 2.32) 
Values in parentheses are 95 per cent c.i. *Adjusted for all other variables in the table. HR, hazard 
ratio. 
  
Table 3 Rates of venous thromboembolism for emergency admission, by indication, age, co-
morbidity using the Charlson index, body mass index and smoking 
  Rate per 1000 person-years Unadjusted HR Adjusted HR* 
Indication 
   
Non-malignant 23.1 (16.88, 31.62) 1.00 (reference) 1.00 (reference) 
Malignant 61.44 (49.14, 76.82) 2.59 (1.76, 3.80) 2.42 (1.61, 3.65) 
Age (years) 
   
< 40 16.04 (7.21, 35.71) 1.00 (reference) 1.00 (reference) 
40–49 30.44 (15.22, 60.87) 1.91 (0.66, 5.51) 1.48 (0.51, 4.30) 
50–59 24.3 (13.07, 45.15) 1.51 (0.55, 4.15) 1.03 (0.37, 2.88) 
60–69 54.98 (39.09, 77.34) 3.35 (1.40, 8.00) 2.06 (0.83, 5.09) 
70–79 60.19 (45.08, 80.36) 3.61 (1.54, 8.46) 2.14 (0.87, 5.28) 
> 80 24.6 (14.28, 42.36) 1.44 (0.55, 3.79) 0.83 (0.30, 2.32) 
No. of co-morbidities 
   
0 42.13 (32.85, 54.04) 1.00 (reference) 1.00 (reference) 
1 33.36 (21.52, 51.71) 0.79 (0.48, 1.31) 0.76 (0.45, 1.27) 
2 29.17 (16.94, 50.23) 0.68 (0.38, 1.24) 0.52 (0.28, 0.95) 
≥ 3 49.45 (32.24, 75.84) 1.12 (0.68, 1.84) 0.85 (0.51, 1.43) 
Body mass index (kg/m2) 
   
< 30 36.84 (29.10, 46.64) 1.00 (reference) 1.00 (reference) 
≥ 30 64.71 (46.00, 91.02) 1.75 (1.15, 2.65) 1.70 (1.11, 2.60) 
Missing 25.07 (14.85, 42.33) 0.67 (0.38, 1.19) 0.83 (0.43, 1.62) 
Smoking status 
   
Never 28.51 (17.72, 45.85) 1.00 (reference) 1.00 (reference) 
Ever 46.16 (35.92, 59.33) 1.60 (0.94, 2.75) 1.39 (0.80, 2.41) 
Current 42.89 (30.49, 47.27) 1.49 (0.83, 2.68) 1.24 (0.68, 2.26) 
Missing 19.67 (8.19, 47.27) 0.68 (0.25, 1.83) 0.83 (0.27, 2.55) 
Values in parentheses are 95 per cent c.i. *Adjusted for all other variables in the table. HR, hazard ratio. 
  
Table 4 Rates of venous thromboembolism in the first month after surgery, by admission 
type and indication 
 Rate (per 1000 person-years)  
First month after surgery Time from first month to 1 year Adjusted HR* 
Elective    
Non-malignant 12.98 (3.25, 51.89) 5.65 (2.94, 10.86) 1.00 (reference) 
Malignant 61.83 (43.96, 86.98) 28.56 (24.36, 33.48) 3.81 (0.90, 15.99) 
Emergency 
   
Non-malignant 114.76 (73.20, 179.91) 13.13 (8.47, 20.36) 1.00 (reference) 
Malignant 120.98 (74.12, 197.48) 54.42 (42.34, 69.94) 1.12 (0.56, 2.27) 
Values in parentheses are 95 per cent c.i. *Cox regression analysis adjusted for age and sex. HR, 
hazard ratio. 
  
Table 5 Rates of venous thromboembolism in the first month after discharge from hospital, 
by admission type and indication 
 Rate in first month after hospital discharge (per 1000 person-years) 
Elective  
Non-malignant 13.18 (3.29, 52.71) 
Malignant 68.76 (49.61, 95.33) 
Emergency  
Non-malignant 78.01 (44.31, 137.36) 
Malignant 106.38 (61.77, 183.21) 
Values in parentheses are 95 per cent c.i. 
 
 
 
